Results 91 to 100 of about 13,106 (183)

Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?

American Journal of Hematology, Volume 101, Issue 8, Page 1783-1789, August 2026.
Sudhir Tauro, Ayalew Tefferi
wiley   +1 more source

Integrated Transcriptomic and Functional Analyses Reveal lncRNA‐miRNA‐mRNA Axis in AML Relapse After Allo‐HSCT

Cancer Science, Volume 117, Issue 8, Page 2289-2304, August 2026.
Transcriptomic profiling of CD34+ cells from AML patients relapsing after allo‐HSCT reveals lncRNA‐driven ceRNA networks, with the SNHG8‐miR‐625‐ZC3H13/15 axis identified as a key relapse‐promoting module through CRISPR screening and single‐cell perturbation.
Fei Zhao, Wenhao Wang, Hongye Gao, Ping Zhu, Weihua Zhai, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han, Lina Wu, Shukai Qiao, Lei Zhang, Erlie Jiang, Xiaolei Pei, Donglin Yang   +14 more
wiley   +1 more source

The Natural Quassinoid Brusatol Enhances Venetoclax Efficacy and Overcomes Resistance in Myeloid Leukemias

Cancer Science, Volume 117, Issue 8, Page 2274-2288, August 2026.
Schematic illustration of the mechanisms by which the natural quassinoid brusatol induces apoptosis in myeloid leukemias and enhances venetoclax efficacy via p53‐dependent apoptosis and mitochondrial dysfunction. ABSTRACT While venetoclax‐based combinations have shown promising results in acute myeloid leukemia (AML), the remission duration is ...
Shin‐ichiro Kawaguchi, Kazuya Sato, Junko Izawa, Norihito Takayama, Hiroko Hayakawa, Ken Suzaki, Susumu Goyama, Chiyoko Kato, Eiji Sakashita, Kaoru Tominaga, Hitoshi Endo, Yoshinobu Kanda   +11 more
wiley   +1 more source

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML

Annals of Hematology
Background Oral azacitidine improves survival in patients with AML in first complete remission who are not candidates for allogeneic transplantation. Most favorable-risk AML patients harbor molecular markers enabling sensitive measurable residual disease
Noa Hurvitz, Irina Amitai, Ilana Levy Yurkovski, Ariella Tvito, Yishai Ofran, Tzvika Porges, Ofir Wolach, Adi Sherban, Noa Gross Even-Zohar, Vladimir Vainstein, Arnon Haran, Shlomzion Aumann, Robert Mikhelashvili, Avraham Frisch, Boaz Nachmias   +14 more
doaj   +1 more source

DNA Methylation Shapes Seed‐Borne Microbiome and Proteome Responses During Early Maize‐Beneficial Bacteria Interactions

Plant, Cell &Environment, Volume 49, Issue 8, Page 5477-5496, August 2026.
ABSTRACT Microorganism and plant interactions are crucial for development and environmental adaptation. Plant growth promoting bacteria enhance agricultural productivity in a sustainable manner, while epigenetic modifications such as DNA methylation regulate gene expression and adaptive responses.
Pedro Igor Zocateli, Geovanna Vitória Olímpio, Felipe Astolpho de Almeida, Letícia Oliveira da Rocha, Diego Vinicius de Sena Martins, Sara Sangi, Fábio Lopes Olivares, Elyabe Monteiro de Matos, Juliana Siqueira, Lyderson Facio Viccini, Roberta Pena da Paschoa, Vanildo Silveira, Clícia Grativol   +12 more
wiley   +1 more source

Anaphylactic transfusion reaction to group B platelets related to alpha‐gal syndrome: A case report

Transfusion, Volume 66, Issue 8, Page 1690-1693, August 2026.
Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Oscar Andre Hinojosa, Amitava Dasgupta, Zhan Ye   +2 more
wiley   +1 more source

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study

British Journal of Haematology, Volume 209, Issue 2, Page 799-803, August 2026.
Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri   +14 more
wiley   +1 more source

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients

British Journal of Haematology, Volume 209, Issue 2, Page 793-798, August 2026.
Sari Kytölä, Anu Partanen, Milla E. L. Kuusisto, Sirpa Koskela, Annasofia Holopainen, Ida Vänttinen, Tanja Ruokoranta, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro   +12 more
wiley   +1 more source

The First Reported Case of VEXAS Syndrome in Lebanon: Efficacy of Azacitidine as a Therapeutic Option-Case Report. [PDF]

Case Rep Hematol
Issa R, Akiki B, Georgin-Lavialle S, Kosmider O, Hammond D, Massoud M, Najjar V, Dagher E.   +7 more
europepmc   +1 more source

Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report. [PDF]

Front Immunol
Sato K, Zaimoku Y, Kano Y, Kobayashi M, Kazama S, Morikawa T, Kazumoto H, Ishii W, Ueki T, Sumi M, Kobayashi H, Nannya Y, Ogawa S, Ichikawa N.   +13 more
europepmc   +1 more source